Evidence map›Paper›PMID 37615850›Full record

Trial reportAdvances in therapy2023

Ramipril for the Treatment of COVID-19: RAMIC, a Randomized, Double-Blind, Placebo-Controlled Clinical Trial.

Daniel Q Huang, Veeral Ajmera, Christian Tomaszewski, Andrew LaFree, Ricki Bettencourt, Wesley K Thompson, Davey M Smith, Atul Malhotra, Ravindra L Mehta, Vaishal Tolia and 19 more

Registry-linked trialOpen access · greenAbstract readRandomized Controlled TrialMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Advances in therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04366050 (A Randomized, Double-blind, Placebo-Controlled Trial to Evaluate the Efficacy of Ramipril to Prevent ICU Admission, Need for Mechanical Ventilation or Death in Persons With COVID-19), which is not on this map. Cited by 4 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 2 pooled it
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04366050 phase2completednot on this map

A Randomized, Double-blind, Placebo-Controlled Trial to Evaluate the Efficacy of Ramipril to Prevent ICU Admission, Need for Mechanical Ventilation or Death in Persons With COVID-19

TypeinterventionalSponsorUniversity of California, San DiegoRan2020 to 2021Enrolled160ConditionsCOVID-19ArmsRamipril 2.5 MG Oral Capsule, Placebo oral capsule
3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 2 syntheses or guidelines pooled it, 4 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors at 11 institutions in 2 countries.

Daniel Q Huang *NAFLD Research Center, Division of Gastroenterology, University of California at San Diego, La Jolla, CA, USA.
Veeral Ajmera *NAFLD Research Center, Division of Gastroenterology, University of California at San Diego, La Jolla, CA, USA.
Christian TomaszewskiDepartment of Emergency Medicine, University of California, San Diego and the El Centro Regional Medical Center, San Diego, CA, USA.
Andrew LaFreeDepartment of Emergency Medicine, University of California, San Diego and the El Centro Regional Medical Center, San Diego, CA, USA.
Ricki BettencourtNAFLD Research Center, Division of Gastroenterology, University of California at San Diego, La Jolla, CA, USA.
Wesley K ThompsonDivision of Biostatistics and Bioinformatics, Department of Family Medicine and Public Health, University of California San Diego, La Jolla, CA, USA.
Davey M SmithDivision of Infectious Diseases and Global Public Health, Department of Medicine, University of California San Diego, La Jolla, CA, USA.
Atul MalhotraDivision of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, University of California San Diego, La Jolla, CA, USA.
Ravindra L MehtaDivision of Nephrology-Hypertension, Department of Medicine, University of California San Diego, La Jolla, CA, USA.
Vaishal ToliaDepartment of Emergency Medicine, University of California San Diego, La Jolla, CA, USA.
Jeffrey YinDepartment of Pharmacy, University of California San Diego, La Jolla, CA, USA.
Paul A InselDepartment of Pharmacology, University of California San Diego, La Jolla, CA, USA.
Stone LeachmanNAFLD Research Center, Division of Gastroenterology, University of California at San Diego, La Jolla, CA, USA.
Jinho JungNAFLD Research Center, Division of Gastroenterology, University of California at San Diego, La Jolla, CA, USA.
Summer CollierDivision of Gastroenterology, Department of Medicine, University of California San Diego, La Jolla, CA, USA.
Lisa RichardsNAFLD Research Center, Division of Gastroenterology, University of California at San Diego, La Jolla, CA, USA.
Kristin WoodsClinical & Translational Research Institute, University of California, San Diego, La Jolla, CA, USA.
Maral AmangurbanovaNAFLD Research Center, Division of Gastroenterology, University of California at San Diego, La Jolla, CA, USA.
Archana BhattClinical & Translational Research Institute, University of California, San Diego, La Jolla, CA, USA.
Xinlian ZhangDivision of Biostatistics and Bioinformatics, Herbert Wertheim School of Public Health, University of California San Diego, San Diego, CA, USA.
Oana M PenciuBeverly Hospital, Montebello, CA, USA.
Stuart ZarichSection of Cardiovascular Medicine, Yale New Haven Health Bridgeport Hospital, Bridgeport, CT, USA.
Tamrat RettaDepartment of Internal Medicine, Howard University, Washington, DC, USA.
Michelle S HarkinsDepartment of Internal Medicine, University of New Mexico, Albuquerque, NM, USA.
J Pedro TeixeiraDepartment of Internal Medicine, University of New Mexico, Albuquerque, NM, USA.
Brian ChinnockDepartment of Emergency Medicine, University of California San Francisco-Fresno Medical Education Program, Fresno, CA, USA.
Netanya S UtayDivision of Infectious Diseases and Geographic Medicine, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Jordan E LakeDivision of Infectious Diseases, Department of Internal Medicine, McGovern Medical School, University of Texas Health Science Center, Houston, TX, USA.
Rohit LoombaNAFLD Research Center, Division of Gastroenterology, University of California at San Diego, La Jolla, CA, USA. roloomba@ucsd.edu.
University of California, San Diego · USRegional Medical Center · USUniversity of New Mexico · USBeverly Hospital · USBridgeport Hospital · USCalifornia State University, Fresno · USHoward University · USThe University of Texas Health Science Center at Houston · USThe University of Texas Southwestern Medical Center · USUniversity of California System · USVeterans Health Administration · US

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
UC San Diego Clinical and Translational Research InstituteUL1TR001442 · NCATS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI FIRESTEIN, GARY S, HOGARTH, MICHAEL · 2015 to 2024
$88.3M
Yeast Genetics and Stress Response Genes-BiomedicalP42ES010337 · NIEHS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI TUKEY, ROBERT H · 2000 to 2022
$69.8M
UNM HSC Clinical and Translational Science CenterUL1TR001449 · NCATS · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI CAMPEN, MATTHEW J, PANDHI, NANCY · 2015 to 2024
$36.9M
Pediatric Trials in Non-Alcoholic Steatohepatitis (NASH)U01DK061734 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI ROHIT LOOMBA · 2002 to 2026
$24.4M
Tissue-specific roles of FXR in CVD and NASHP01HL147835 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI LOOMBA, ROHIT · 2020 to 2024
$12.2M
San Diego Digestive Diseases Research CenterP30DK120515 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Bernd G. Schnabl · 2019 to 2026
$10.8M
HIV MASLD Clinical Research Network (HCRN)R01DK121378 · NIDDK · INDIANA UNIVERSITY INDIANAPOLIS · PI NAGA P CHALASANI, ROHIT LOOMBA · 2020 to 2026
$8.7M
Is Obstructive Sleep Apnea Important in the Development of Alzheimer's DiseaseR01AG063925 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI MALHOTRA, ATUL · 2020 to 2024
$3.7M
Underlying mechanisms of obesity-induced obstructive sleep apneaR01HL148436 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Atul Malhotra · 2020 to 2026
$3.4M
QUS Technology for Diagnosis and Grading of Hepatic Steatosis in NAFLDR01DK106419 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI LOOMBA, ROHIT, SIRLIN, CLAUDE B · 2015 to 2019
$3.4M
Sleep Apnea Endophenotypes: One Size Does Not Fit AllR01HL154926 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI MALHOTRA, ATUL · 2021 to 2025
$3.3M
NCATS NIH HHS UL1 TR001442NCATS NIH HHS UL1 TR001449NCATS NIH HHS UL1 TR001863NHLBI NIH HHS P01 HL147835NHLBI NIH HHS R01 HL148436NHLBI NIH HHS R01 HL154926NHLBI NIH HHS R01 HL157985NHLBI NIH HHS R01 HL166485NHLBI NIH HHS T32 HL134632NHLBI NIH HHS T32 HL166127NIA NIH HHS R01 AG063925NIDDK NIH HHS P30 DK120515NIDDK NIH HHS R01 DK106419NIDDK NIH HHS R01 DK121378NIDDK NIH HHS R01 DK124318NIDDK NIH HHS U01 DK061734NIDDK NIH HHS U01 DK130190NIEHS NIH HHS P42 ES010337
6 · The paper itself

Abstract

introductionRetrospective studies report that angiotensin-converting enzyme inhibitors (ACEIs) may reduce the severity of COVID-19, but prospective data on de novo treatment with ACEIs are limited. The RAMIC trial was a randomized, multicenter, placebo-controlled, double-blind, allocation-concealed clinical trial to examine the efficacy of de novo ramipril versus placebo for the treatment of COVID-19.

methodsEligible participants were aged 18 years and older with a confirmed diagnosis of SARS-CoV-2 infection, recruited from urgent care clinics, emergency departments, and hospital inpatient wards at eight sites in the USA. Participants were randomly assigned to daily ramipril 2.5 mg or placebo orally in a 2:1 ratio, using permuted block randomization. Analyses were conducted on an intention-to-treat basis. The primary outcome was a composite of mortality, intensive care unit (ICU) admission, or invasive mechanical ventilation by day 14.

resultsBetween 27 May 2020 and 19 April 2021, a total of 114 participants (51% female) were randomized to ramipril (n = 79) or placebo (n = 35). The overall mean (± SD) age and BMI were 45 (± 15) years and 33 (± 8) kg/m

conclusionDe novo ramipril was not different compared with placebo in improving or worsening clinical outcomes from COVID-19 but appeared safe in non-critically ill patients with COVID-19.

trial registrationClinicaltrials.gov NCT04366050.

Indexed as

COVID-19Angiotensin-Converting Enzyme InhibitorsDouble-Blind MethodFemaleHumansMaleProspective StudiesRamiprilRetrospective StudiesSARS-CoV-2Treatment OutcomeAngiotensin-Converting Enzyme InhibitorsRamiprilCoronavirusCOVID-19RamiprilTherapy

Identifiers

PMID37615850
PMCPMC10709987
OpenAlexW4386116256

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.